Non-medical users of anabolic steroids often “stack” different anabolic steroids over the course of a “cycle” of use. They also administer various ancillary drugs and substances to enhance the desired effects of anabolic steroids or to minimize adverse side effects. The most common liquid (injectable) anabolic steroids encountered in these cases are (oil-based) esters of testosterone (., testosterone cypionate, testosterone enanthate, and testosterone propionate, and a blend of testosterone esters called Sustanon 250) or nandrolone (., nandrolone decanoate). Also popular are Equipoise (boldenone undecylenate) and trenbolone acetate and trenbolone enanthate, as well as the water-based injectable Winstrol (stanozolol). Popular oral anabolic steroids include methandrostenolone (Dianbol), oxandrolone (Anavar) and oxymetholone (Anadrol 50).
After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .